WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526788

CAS#: 355025-24-0

Description: Ki16425 is a LPA receptor antagonist with selectivity for LPA1 and LPA3. It exhibits Ki values of 0.34, 6.5, and 0.93 µM for the human LPA1, LPA2, and LPA3 receptors, respectively. Ki16425 reduces nerve growth factor-induced neurite outgrowth in pheochromocytoma 12 cells. ki16425 blunts abdominal and systemic inflammation in a mouse model of peritoneal sepsis.

Price and Availability

Size Price Shipping out time Quantity
200mg USD 950 2 Weeks
500mg USD 1450 2 Weeks
1g USD 2550 2 Weeks
2g USD 4250 2 Weeks
5g USD 6950 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-20. Prices are subject to change without notice.

Ki16425, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 526788
Name: Ki16425
CAS#: 355025-24-0
Chemical Formula: C23H23ClN2O5S
Exact Mass: 474.1016
Molecular Weight: 474.956
Elemental Analysis: C, 58.16; H, 4.88; Cl, 7.46; N, 5.90; O, 16.84; S, 6.75

Synonym: Ki16425; Ki-16425; Ki 16425.

IUPAC/Chemical Name: 3-((4-(4-(((1-(2-chlorophenyl)ethoxy)carbonyl)amino)-3-methylisoxazol-5-yl)benzyl)thio)propanoic acid


InChi Code: InChI=1S/C23H23ClN2O5S/c1-14-21(25-23(29)30-15(2)18-5-3-4-6-19(18)24)22(31-26-14)17-9-7-16(8-10-17)13-32-12-11-20(27)28/h3-10,15H,11-13H2,1-2H3,(H,25,29)(H,27,28)


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Zhao J, Wei J, Weathington N, Jacko AM, Huang H, Tsung A, Zhao Y. Lysophosphatidic acid receptor 1 antagonist ki16425 blunts abdominal and systemic inflammation in a mouse model of peritoneal sepsis. Transl Res. 2015 Jul;166(1):80-8. doi: 10.1016/j.trsl.2015.01.008. Epub 2015 Jan 31. PubMed PMID: 25701366; PubMed Central PMCID: PMC4458421.

2: Sato T, Sugimoto K, Inoue A, Okudaira S, Aoki J, Tokuyama H. Synthesis and biological evaluation of optically active Ki16425. Bioorg Med Chem Lett. 2012 Jul 1;22(13):4323-6. doi: 10.1016/j.bmcl.2012.05.012. Epub 2012 May 11. PubMed PMID: 22658556.

3: Kim K, Kim HL, Lee YK, Han M, Sacket SJ, Jo JY, Kim YL, Im DS. Lysophosphatidylserine induces calcium signaling through Ki16425/VPC32183-sensitive GPCR in bone marrow-derived mast cells and in C6 glioma and colon cancer cells. Arch Pharm Res. 2008 Mar;31(3):310-7. doi: 10.1007/s12272-001-1157-x. Epub 2008 Apr 13. PubMed PMID: 18409043.

4: Moughal NA, Waters CM, Valentine WJ, Connell M, Richardson JC, Tigyi G, Pyne S, Pyne NJ. Protean agonism of the lysophosphatidic acid receptor-1 with Ki16425 reduces nerve growth factor-induced neurite outgrowth in pheochromocytoma 12 cells. J Neurochem. 2006 Sep;98(6):1920-9. PubMed PMID: 16945108.

5: Ohta H, Sato K, Murata N, Damirin A, Malchinkhuu E, Kon J, Kimura T, Tobo M, Yamazaki Y, Watanabe T, Yagi M, Sato M, Suzuki R, Murooka H, Sakai T, Nishitoba T, Im DS, Nochi H, Tamoto K, Tomura H, Okajima F. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol. 2003 Oct;64(4):994-1005. PubMed PMID: 14500756.